These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 20043095

  • 1. Antitumor effects of telomelysin in combination with paclitaxel or cisplatin on head and neck squamous cell carcinoma.
    Kondo N, Tsukuda M, Kimura M, Fujita K, Sakakibara A, Takahashi H, Ishiguro Y, Toth G, Matsuda H.
    Oncol Rep; 2010 Feb; 23(2):355-63. PubMed ID: 20043095
    [Abstract] [Full Text] [Related]

  • 2. Examination of the optimal condition on the in vitro sensitivity to telomelysin in head and neck cancer cell lines.
    Sakakibara A, Tsukuda M, Kondo N, Ishiguro Y, Kimura M, Fujita K, Takahashi H, Matsuda H.
    Auris Nasus Larynx; 2011 Oct; 38(5):589-99. PubMed ID: 21362583
    [Abstract] [Full Text] [Related]

  • 3. Telomerase-specific virotheranostics for human head and neck cancer.
    Kurihara Y, Watanabe Y, Onimatsu H, Kojima T, Shirota T, Hatori M, Liu D, Kyo S, Mizuguchi H, Urata Y, Shintani S, Fujiwara T.
    Clin Cancer Res; 2009 Apr 01; 15(7):2335-43. PubMed ID: 19318473
    [Abstract] [Full Text] [Related]

  • 4. Anti-tumor effects of telomelysin for head and neck squamous cell carcinoma.
    Fujita K, Kimura M, Kondo N, Sakakibara A, Sano D, Ishiguro Y, Tsukuda M.
    Oncol Rep; 2008 Dec 01; 20(6):1363-8. PubMed ID: 19020715
    [Abstract] [Full Text] [Related]

  • 5. Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD').
    Taki M, Kagawa S, Nishizaki M, Mizuguchi H, Hayakawa T, Kyo S, Nagai K, Urata Y, Tanaka N, Fujiwara T.
    Oncogene; 2005 Apr 28; 24(19):3130-40. PubMed ID: 15735729
    [Abstract] [Full Text] [Related]

  • 6. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
    Watanabe T, Hioki M, Fujiwara T, Nishizaki M, Kagawa S, Taki M, Kishimoto H, Endo Y, Urata Y, Tanaka N, Fujiwara T.
    Exp Cell Res; 2006 Feb 01; 312(3):256-65. PubMed ID: 16356494
    [Abstract] [Full Text] [Related]

  • 7. Retargeting improves the efficacy of a telomerase-dependent oncolytic adenovirus for head and neck cancer.
    Toivonen R, Suominen E, Grenman R, Savontaus M.
    Oncol Rep; 2009 Jan 01; 21(1):165-71. PubMed ID: 19082458
    [Abstract] [Full Text] [Related]

  • 8. An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer.
    Zhong S, Yu D, Wang Y, Qiu S, Wu S, Liu XY.
    Acta Oncol; 2010 Jan 01; 49(1):91-9. PubMed ID: 19734998
    [Abstract] [Full Text] [Related]

  • 9. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
    Watanabe Y, Hashimoto Y, Kagawa S, Kawamura H, Nagai K, Tanaka N, Urata Y, Fujiwara T.
    Cancer Gene Ther; 2012 Nov 01; 19(11):767-72. PubMed ID: 22956040
    [Abstract] [Full Text] [Related]

  • 10. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
    Zhang Q, Chen G, Peng L, Wang X, Yang Y, Liu C, Shi W, Su C, Wu H, Liu X, Wu M, Qian Q.
    Clin Cancer Res; 2006 Nov 01; 12(21):6523-31. PubMed ID: 17085667
    [Abstract] [Full Text] [Related]

  • 11. Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma.
    Sung CK, Choi B, Wanna G, Genden EM, Woo SL, Shin EJ.
    Laryngoscope; 2008 Feb 01; 118(2):237-42. PubMed ID: 18043494
    [Abstract] [Full Text] [Related]

  • 12. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
    Irving J, Wang Z, Powell S, O'Sullivan C, Mok M, Murphy B, Cardoza L, Lebkowski JS, Majumdar AS.
    Cancer Gene Ther; 2004 Mar 01; 11(3):174-85. PubMed ID: 14726958
    [Abstract] [Full Text] [Related]

  • 13. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
    Song Y, Shen K, Yu JR.
    Zhonghua Yi Xue Za Zhi; 2007 Nov 06; 87(41):2919-24. PubMed ID: 18261307
    [Abstract] [Full Text] [Related]

  • 14. Combination therapy with radiation or cisplatin enhances the potency of Ad5/35 chimeric oncolytic adenovirus in a preclinical model of head and neck cancer.
    Ganesh S, Gonzalez-Edick M, Gibbons D, Ge Y, VanRoey M, Robinson M, Jooss K.
    Cancer Gene Ther; 2009 May 06; 16(5):383-92. PubMed ID: 19011598
    [Abstract] [Full Text] [Related]

  • 15. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B, Liu X, Fan J, Qi R, Bo L, Gu J, Qian Q, Qian C, Liu X.
    J Gene Med; 2006 Oct 06; 8(10):1232-42. PubMed ID: 16900558
    [Abstract] [Full Text] [Related]

  • 16. Polymer chemotherapy for head and neck cancer.
    Shikani AH, Domb AJ.
    Laryngoscope; 2000 Jun 06; 110(6):907-17. PubMed ID: 10852503
    [Abstract] [Full Text] [Related]

  • 17. Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1.
    Dias JD, Liikanen I, Guse K, Foloppe J, Sloniecka M, Diaconu I, Rantanen V, Eriksson M, Hakkarainen T, Lusky M, Erbs P, Escutenaire S, Kanerva A, Pesonen S, Cerullo V, Hemminki A.
    Clin Cancer Res; 2010 May 01; 16(9):2540-9. PubMed ID: 20388844
    [Abstract] [Full Text] [Related]

  • 18. Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents.
    Knecht R, Peters S, Adunka O, Strebhardt K, Gstoettner W, Hambek M.
    Anticancer Res; 2003 May 01; 23(3B):2577-83. PubMed ID: 12894544
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. In vivo biological purging for lymph node metastasis of human colorectal cancer by telomerase-specific oncolytic virotherapy.
    Kojima T, Watanabe Y, Hashimoto Y, Kuroda S, Yamasaki Y, Yano S, Ouchi M, Tazawa H, Uno F, Kagawa S, Kyo S, Mizuguchi H, Urata Y, Tanaka N, Fujiwara T.
    Ann Surg; 2010 Jun 01; 251(6):1079-86. PubMed ID: 20485131
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.